详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo

94| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

出处：

DOI：

ISSN：

关键词： epithelial-mesenchymal transition glioblastoma therapy IKK epsilon inhibitor MCCK1 temozolomide

摘要：

Chemotherapy with temozolomide (TMZ) is the traditional treatment for glioblastoma (GBM). Nevertheless, majority of GBM patients have recurrence from resistance to the chemotherapy. Herein, we examined combinational effects of MCCK1 (a specific and effective IKK epsilon inhibitor) with TMZ in GBM U251MG and U-87MG cell lines as well as U251MG xenograft models to overcome the therapeutic limitation of chemotherapy for GBM. Although MCCK1 alone showed inhibitory effects on in vitro proliferation, migration, invasion, and EMT of U251MG and U-87MG cells, combination of MCCK1 and TMZ showed enhanced inhibitory effects. In the U251MG GBM xenograft models, MCCK1 showed synergistic therapeutic effects in combination with TMZ to reduce tumor volumes significantly. These data indicated that MCCK1 could be a candidate sensitizer to potentiate therapeutic effects of conventional cytotoxic treatment for GBM.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2017]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 2.9 最新[2023版] 3.9 最新五年平均 3.202 出版当年[2017版] 3.453 出版当年五年平均 3.362 出版前一年[2016版] 3.357 出版后一年[2018版]

第一作者：

第一作者机构： [1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

通讯作者：

通讯机构： [1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China [*1]Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献